TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31335590

Group type: EXPERIMENTAL
Intervention: TDF/FTC (n = 10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TAF/FTC/COBI/EVG (n = 8)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TAF/FTC/COBI/EVG (n = 7)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: TDF/FTC (n = 9)
Number of subjects: 34
Study: 29414980

Group type: EXPERIMENTAL
Intervention: Pre-treatment costs incurred by patients
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Time to treatment initiation
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Health systems delay
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Factors associated with higher direct OOP medical costs
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Factors associated with health systems delay
Number of subjects: 880
Study: 27168361

Group type: EXPERIMENTAL
Intervention: 300 mg V116517
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25639137

Group type: EXPERIMENTAL
Intervention: Meat
Number of subjects: 1471
Study: 22892409

Group type: EXPERIMENTAL
Intervention: Strength training program (3 times per week for 6 weeks using rubber exercise bands and Multiaxial Ankle Exerciser)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 20572379

Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17969366

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 127
Study: 16109908

Group type: EXPERIMENTAL
Intervention: Computerized arm trainer (AT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Electromyography‐initiated electrical stimulation (ES)
Number of subjects: 44
Study: 12111113

Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m(2))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous topotecan (1.5 mg/m(2))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: N-desmethyl topotecan
Number of subjects: 11
Study: 10416208

Group type: EXPERIMENTAL
Intervention: COX-2 NSAID
Number of subjects: 30
Study: 7569824

Group type: EXPERIMENTAL
Intervention: Pneumatic swing phase control (Tehlin knee joint)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mechanical swing phase control (Otto Bock 3R20)
Number of subjects: 28
Study: 2109114

Group type: EXPERIMENTAL
Intervention: Pulmocare (low carbohydrate formula)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ensure Plus (medium carbohydrate formula)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vivonex HN (high carbohydrate formula)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of Pulmocare to Ensure Plus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of Pulmocare to Vivonex HN
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of Vivonex HN to Pulmocare and Ensure Plus
Number of subjects: 10
Study: 6627825

Group type: COMPARATOR
Intervention: Gentamicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Netilmicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Number of subjects: 20
Study: 31588793

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 60

Group type: COMPARATOR
Intervention: GL PVP
Number of subjects: 60

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (HoLEP, GL PVP, TURP)
Number of subjects: 60
Study: 29671128

Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 3.2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 6.3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine succinate 12.7 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Doxylamine succinate 25 mg oral tablet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal doxylamine (all doses)
Number of subjects: 24
Study: 27751707

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo plus bortezomib and dexamethasone
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Panobinostat plus bortezomib and dexamethasone (in patients with at least two previous regimens)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo plus bortezomib and dexamethasone (in patients with at least two previous regimens)
Number of subjects: 768
Study: 25199696

Group type: EXPERIMENTAL
Intervention: Epidural injection of dexamethasone (2 mL, 8 mg)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Normal saline (2 mL)
Number of subjects: 268
Study: 23665915

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 80
Study: 19912273

Group type: EXPERIMENTAL
Intervention: Immediate implant placement into extraction sockets
Number of subjects: 93
Study: 18331601

Group type: EXPERIMENTAL
Intervention: CHOP (doxorubicin 50 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CNOP (mitoxantrone 10-12 mg/m2)
Number of subjects: 0
Study: 16027794

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 54
Study: 14634144

Group type: EXPERIMENTAL
Intervention: Oral estriol treatment
Number of subjects: 0
Study: 10680109

Group type: EXPERIMENTAL
Intervention: Epidural ketamine (0.2 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (100 micrograms)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epidural midazolam (500 micrograms)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (2 mg epidural morphine)
Number of subjects: 48
Study: 8735759

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 91

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 91
Study: 1768504

Group type: EXPERIMENTAL
Intervention: 50% dextrose water (D)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 25% mannitol (M)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 23.5% saline (S)
Number of subjects: 24

Group type: COMPARATOR
Intervention: All three agents (D, M, S)
Number of subjects: 24
Study: 6450001

Group type: EXPERIMENTAL
Intervention: Plasma levels of beta-thromboglobulin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Plasma levels of platelet factor 4
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Plasma levels of thromboxane B2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Plasma levels of fibrinopeptide A
Number of subjects: 19
Study: 31845587

Group type: EXPERIMENTAL
Intervention: Valproate with 24 weeks of atypical antipsychotic
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lithium with 24 weeks of atypical antipsychotic
Number of subjects: 159

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 159

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 159
Study: 31499383

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg/m2/d for 14 days
Number of subjects: 174

Group type: COMPARATOR
Intervention: Dexamethasone 6 mg/m2/d for 28 days (standard dosing)
Number of subjects: 174
Study: 28630378

Group type: EXPERIMENTAL
Intervention: blue-enriched white light (17,000 K, 89 lux; n=36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: standard white light (4000 K, 84 lux; n=35)
Number of subjects: 71
Study: 27063678

Group type: EXPERIMENTAL
Intervention: Volunteer support for self-managed computerised aphasia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and ongoing structured support from a trained speech-language pathologist
Number of subjects: 0
Study: 23843178

Group type: EXPERIMENTAL
Intervention: Visual pattern group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual random group
Number of subjects: 0
Study: 22360874

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 2198

Group type: EXPERIMENTAL
Intervention: Memory improvement intervention
Number of subjects: 2198
Study: 19509381

Group type: EXPERIMENTAL
Intervention: Best-practice CCTA scan model (minimized scan range, heart rate reduction, electrocardiographic-gated tube current modulation, reduced tube voltage)
Number of subjects: 4995

Group type: EXPERIMENTAL
Intervention: Best-practice CCTA scan model
Number of subjects: 4995

Group type: COMPARATOR
Intervention: Control period (July-August 2007)
Number of subjects: 4995
Study: 17906429

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressings under 4-layer compression bandages
Number of subjects: 15
Study: 15361493

Group type: COMPARATOR
Intervention: Nutrient challenge
Number of subjects: 482

Group type: COMPARATOR
Intervention: Gastric emptying time (GET)
Number of subjects: 482
Study: 11224838

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9588664

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8026027

Group type: EXPERIMENTAL
Intervention: lovastatin 80 mg/d
Number of subjects: 270

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 270
Study: 2574905

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Olsalazine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentasa
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salofalk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Asacol
Number of subjects: 8
Study: 53555

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally
Number of subjects: 5
Study: 30389897

Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR) with >3 passes
Number of subjects: 281

Group type: COMPARATOR
Intervention: Stent Retriever (SR) with ≤3 passes
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA) with >3 passes
Number of subjects: 281

Group type: COMPARATOR
Intervention: Contact Aspiration (CA) with ≤3 passes
Number of subjects: 281
Study: 28841537

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study: 25568167

Group type: EXPERIMENTAL
Intervention: Informed cytology for HPV-positive women
Number of subjects: 0
Study: 23452864

Group type: EXPERIMENTAL
Intervention: Community-based hygiene intervention led by Community Motivators promoting hand-washing with soap
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 21190985

Group type: EXPERIMENTAL
Intervention: 10 mg twice daily lorcaserin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 18342968

Group type: EXPERIMENTAL
Intervention: Doranidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15730351

Group type: EXPERIMENTAL
Intervention: Tiagabine 20 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 14514943

Group type: EXPERIMENTAL
Intervention: Acute PVW (n=84)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Convalescence (n=20)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Current wheeze (n=18)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal controls (n=15)
Number of subjects: 84
Study: 10663002

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General Anesthesia (AA)
Number of subjects: 60
Study: 8867534

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1618109

Group type: EXPERIMENTAL
Intervention: Fluorouracil (400 mg/m2 daily for 5 days)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Fluorouracil combined with folic acid (100 mg/m2 before each dose of fluorouracil)
Number of subjects: 139
Study: 6324332

Group type: EXPERIMENTAL
Intervention: Ranitidine tablets, 150 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study: 31187447

Group type: EXPERIMENTAL
Intervention: Bergamot oil nanospanlastics combined with PUVB therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bergamot oil nanospanlastics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spanlastics
Number of subjects: 0
Study: 30672225

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 0
Study: 26547718

Group type: EXPERIMENTAL
Intervention: Revised version of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Standard version of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Both versions of the FDA Drug Safety Communication (DSC)
Number of subjects: 1244
Study: 24740826

Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) with bevacizumab (B, 15 mg/kg q3w)
Number of subjects: 1948

Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) without bevacizumab
Number of subjects: 1948
Study: 22038481

Group type: EXPERIMENTAL
Intervention: Supportive care intervention (details not specified)
Number of subjects: 108
Study: 20404353

Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin (100-148 mg/kg/d)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Low-dose vigabatrin (18-36 mg/kg/d)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Follow-up cohort
Number of subjects: 221
Study: 28933338

Group type: EXPERIMENTAL
Intervention: 24 µg of lubiprostone 30 minutes prior to the study
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 24 µg of lubiprostone plus 10 mg of domperidone 30 minutes prior to the study
Number of subjects: 80

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 80
Study: 12603500

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 12 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Losartan and Control group
Number of subjects: 23
Study: 11061253

Group type: COMPARATOR
Intervention: Riluzole 100 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Riluzole 200 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 43
Study: 9359740

Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis vaccine (SA14-14-2)
Number of subjects: 26239

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 26239
Study: 8228195

Group type: EXPERIMENTAL
Intervention: Self-paced condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Externally paced condition
Number of subjects: 40
Study: 2419635

Group type: EXPERIMENTAL
Intervention: Low molecular hydroxyethyl starch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low molecular dextran
Number of subjects: 0
Study: 29597007

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 950

Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 950
Study: 26617202

Group type: EXPERIMENTAL
Intervention: S-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day break)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Taxane (docetaxel 60-75 mg/m2 at intervals of 3-4 weeks; paclitaxel 80-100 mg/m2 weekly for 3 of 4 weeks; or paclitaxel 175 mg/m2 at intervals of 3-4 weeks)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 618

Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 618
Study: 25465683

Group type: EXPERIMENTAL
Intervention: Transepithelial corneal collagen crosslinking (CXL)
Number of subjects: 25
Study: 22898443

Group type: EXPERIMENTAL
Intervention: Benzodiazepine loading protocol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Symptom-triggered treatment protocol
Number of subjects: 47
Study: 19664302

Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 2 g/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 4 g/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 6 g/d
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sunola oil (control; 6 g/d)
Number of subjects: 67
Study: 18678802

Group type: EXPERIMENTAL
Intervention: Physical therapy (n = 33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (n = 32)
Number of subjects: 65
Study: 15358441

Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles + 800 mg of vaginal progesterone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous pregnanolone (3alpha‐hydroxy‐5beta‐pregnan‐20‐one)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: E(2) alone or E(2)+progesterone
Number of subjects: 26
Study: 12618680

Group type: EXPERIMENTAL
Intervention: Selective stent placement
Number of subjects: 227

Group type: COMPARATOR
Intervention: Systematic stent placement
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stent (Selective)
Number of subjects: 227
Study: 10227648

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8914872

Group type: EXPERIMENTAL
Intervention: Nonthoracotomy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Nonthoracotomy (in patients with left ventricular ejection fraction <30%)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Thoracotomy (in patients with left ventricular ejection fraction <30%)
Number of subjects: 193
Study: 1725537

Group type: EXPERIMENTAL
Intervention: Long-acting diltiazem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6316307

Group type: EXPERIMENTAL
Intervention: High fibre, low fat and low sodium dietary regime
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 53
Study: 31996395

Group type: EXPERIMENTAL
Intervention: SBRT+anti-CTLA4
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SBRT+anti-PD1
Number of subjects: 33
Study: 30059995

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 1842

Group type: COMPARATOR
Intervention: LED-FM
Number of subjects: 1842

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay (subgroup analysis)
Number of subjects: 1842
Study: 28072459

Group type: EXPERIMENTAL
Intervention: Motivational interviewing integrated with cognitive behavioral therapy (MI-CBT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) alone
Number of subjects: 8
Study: 26651463

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microrandomized trials
Number of subjects: 0
Study: 24366622

Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine concentration
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Bone mineral density
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine increase of 5.0 μmol/l
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine level
Number of subjects: 258
Study: 23167181

Group type: EXPERIMENTAL
Intervention: Surgery plus antifungal therapy during operation and postoperation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 102
Study: 19419318

Group type: EXPERIMENTAL
Intervention: FRAX with FN BMD
Number of subjects: 3221

Group type: EXPERIMENTAL
Intervention: FRAX without FN BMD
Number of subjects: 3221

Group type: EXPERIMENTAL
Intervention: Prevalent vertebral fracture plus age and FN BMD
Number of subjects: 3221

Group type: EXPERIMENTAL
Intervention: Combination of prevalent vertebral fracture and FRAX with FN BMD
Number of subjects: 3221

Group type: EXPERIMENTAL
Intervention: Baseline vertebral fracture status plus age and FN BMD
Number of subjects: 3221

Group type: EXPERIMENTAL
Intervention: FRAX for major osteoporotic fractures (with and without FN BMD)
Number of subjects: 3221
Study: 17717245

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV normal saline (Control)
Number of subjects: 100
Study: 15597657

Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 42

Group type: COMPARATOR
Intervention: Posterior approach
Number of subjects: 42
Study: 11276268

Group type: EXPERIMENTAL
Intervention: 2 arm supports
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 arm support
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 9412659

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (n = 5)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oral morphine (n = 6)
Number of subjects: 11
Study: 8505824

Group type: EXPERIMENTAL
Intervention: Perioperative total parenteral nutrition (TPN)
Number of subjects: 0
Study: 3325316

Group type: EXPERIMENTAL
Intervention: 200 mg fentiazac twice daily for 3 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: 50 mg diclofenac sodium twice daily for 3 weeks
Number of subjects: 19
Study: 29642492

Group type: EXPERIMENTAL
Intervention: Trp-3.0g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trp-1.5g
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 27193744

Group type: EXPERIMENTAL
Intervention: Heated humidifier (HH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-heated humidifier (non-HH)
Number of subjects: 40
Study: 25749595

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 90